Communicators

Company Update

Creso Pharma Limited (ASX: CPH, the “Company” or “Creso”) is pleased to advise that regulatory approval from ASX for the shareholder meeting document to approve the transaction with Kunna Canada Ltd (“Kunna Acquisition”) has now been received.

Enclosed is a Notice of Meeting for a shareholders’ meeting to beheld on 16th October 2018 at 10:00am (WST).

Subject to the receipt of shareholder approval, Creso anticipates completing the Kunna Acquisition in mid-October 2018 and thereafter immediately advancing is business plan in Colombia.

Since first executing the agreement relating to the Kunna Acquisition, Colombia has cemented its place as the international jurisdiction of choice for low cost, high quality cannabis production.  There have been multiple international (mainly Canadian) companies that have announced transactions to enter Colombia, including from the world’s largest cannabis company Canopy Growth Corp in a transaction worth up to US$96 million.

These transactions have vindicated Creso’s move into Colombia and should provide investors with additional comfort in relation to Creso’s strategy.

Creso further notes that, on 31 July 2018, Creso’s Quarterly Activities Report stated that that the Company had completed the Kunna Acquisition.  The Company intended for this to disclose that due diligence had been completed in relation to the Kunna Acquisition.  Completion has not occurred and these statements are hereby retracted by Creso.  As noted above, completion is now anticipated to occur in mid-October 2018 (subject to the receipt of shareholder approval).

Corporate Queries:  

EverBlu Capital

Level 39, Aurora Place

88 Phillip Street, Sydney, NSW 2000

E: info@everblucapital.com

P: +61 2 8249 0000